--- title: "U.S. stock night market fluctuations: Phase III trial success for myositis, Argenx rises 9.25% in after-hours trading" type: "News" locale: "en" url: "https://longbridge.com/en/news/296065913.md" description: "Argenx rose 9.25% in after-hours trading; BeiGene rose 2.07% in after-hours trading, with a transaction volume of USD 8.34 million; Capricor Therapeutics rose 3.31% in after-hours trading, with a transaction volume of USD 5.8 million; Skye Bioscience rose 35.41% in after-hours trading, with a transaction volume of USD 1.8 million" datetime: "2026-08-17T06:57:02.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296065913.md) - [en](https://longbridge.com/en/news/296065913.md) - [zh-HK](https://longbridge.com/zh-HK/news/296065913.md) generator: "portal-rs" --- # U.S. stock night market fluctuations: Phase III trial success for myositis, Argenx rises 9.25% in after-hours trading **U.S. Stock Night Market Movements** Argenx rose 9.25% in the night market. Based on recent key news: 1. On August 17, Argenx announced that its drug efgartigimod achieved positive results in a Phase III trial for the treatment of autoimmune myositis. The trial reached its primary endpoint at week 52, showing early and sustained improvement, and the drug was well tolerated. This news drove the stock price up. 2. On August 17, market attention on Argenx increased as it announced positive results from the Phase III trial of efgartigimod. The drug significantly improved disease activity, reached its primary endpoint, and demonstrated multidimensional benefits with good safety. 3. On August 17, Argenx's drug efgartigimod showed significant efficacy and safety in the Phase III trial, further boosting investor confidence and driving the stock price up. The market remains focused on the situation in the Middle East, with the energy market starting off quietly. **Stocks with High Trading Volume in the Industry** BeiGene rose 2.07% in the night market. Based on recent key news: 1. On August 11, JP Morgan increased its holdings in BeiGene, purchasing 4.11972 million shares for a total amount of approximately HKD 905 million, demonstrating confidence in the company's future development and driving the stock price up. 2. Since August, BeiGene has received research from over 200 institutions, showing high market attention to its innovative drug development, further boosting the stock price. 3. On August 14, the overall attention on the pharmaceutical sector increased, with BeiGene, as a leader in innovative drugs, receiving intensive research from foreign institutions, resulting in strong stock performance. The pharmaceutical sector's attention has increased, and institutional research is active. Capricor Therapeutics rose 3.31%. Based on recent key news: 1. On August 14, the U.S. FDA agreed to review the latest data for Capricor Therapeutics' Duchenne muscular dystrophy drug Deramiocel, driving the stock price up. Cantor Fitzgerald upgraded the stock rating to "buy," significantly raising the target price from $3.50 to $28. This news triggered a mid-day surge of 57.36%, currently reported at $6.625. 2. On August 14, Capricor announced plans to submit supplementary trial data showing benefits of its drug in upper limb muscle function. The FDA expressed willingness to review this amendment and extended the PDUFA action date upon receipt. This move is seen by analysts as a positive shift supporting approval, driving the stock price up. 3. On August 14, Capricor withdrew its lawsuit against NS Pharma and sought arbitration to resolve the commercialization dispute over CAP-1002. This move reduced legal risks, enhanced investor confidence, and further drove the stock price up. The biotechnology industry has been volatile recently and requires attention Skye Bioscience rose 35.41% in after-hours trading. Based on recent key news: 4. On August 14, Skye Bioscience announced a merger with Redx Pharma to form a company focused on fibrosis, securing $125 million in financing. This move boosted market confidence in the company's future development, driving up the stock price. 5. On August 14, the company terminated the development of nimacimab and initiated a cost-cutting plan to address competitive pressures and poor trial results. This action was seen by the market as a positive signal of the company's strategic adjustment, further uplifting the stock price. 6. On August 14, Skye Bioscience planned a reverse stock split to meet NASDAQ compliance requirements while facing ongoing litigation and going concern risks. Despite the risks, investor confidence in the company's compliance measures increased, resulting in a rise in stock price. Recent financing activities in the biotechnology sector have been active ### Related Stocks - [ARGX.US](https://longbridge.com/en/quote/ARGX.US.md) - [ONC.US](https://longbridge.com/en/quote/ONC.US.md) - [CAPR.US](https://longbridge.com/en/quote/CAPR.US.md) - [SKYE.US](https://longbridge.com/en/quote/SKYE.US.md) ## Related News & Research - [argenx (ENXTBR:ARGX) Hits A Phase 3 Win, Is The Upside Fully Priced?](https://longbridge.com/en/news/296529685.md) - [$100 Invested In argenx 5 Years Ago Would Be Worth This Much Today](https://longbridge.com/en/news/296119451.md) - [Argenx Says Phase 3 Alkivia Trial Of Efgartigimod In Autoimmune Myositis Met Primary Endpoint](https://longbridge.com/en/news/296059044.md) - [These Analysts Boost Their Forecasts On Argenx](https://longbridge.com/en/news/296226998.md) - [ARGX: Efgartigimod achieved significant, sustained improvement in autoimmune myositis in Phase 3](https://longbridge.com/en/news/296061848.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**